IP Cases — 2024
4,762 decisions across all jurisdictions
Page 16 of 159 · 4,762 total
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories submits a response urging the PTAB Director to deny Miracor Medical’s request for review of the institution decision in IPR2025-00114. The petitioner argues the Board’s findings on particularity, claim construction, word count, and Fintiv factors were proper and that the request would be inefficient.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
The PTAB denied Abbott Laboratories' request for Director Review of the institution decisions in three IPRs, including IPR2025-00116 covering Miracor Medical's patent 11,754,077 B1. The institution decisions remain in effect.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories’ petition to institute an IPR against Miracor Medical’s heart‑pump patent is challenged by Miracor, which argues the petition lacks particularity, violates claim‑construction rules, and circumvents word‑count limits, seeking discretionary denial under § 314(a).
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of 18 claims of Miracor’s LVAD patent (US 11,754,077). The petition alleges obviousness over four prior‑art references and argues the petition is not barred. The Board’s decision on institution is pending.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s U.S. Patent 11,572,879 covering an implantable LVAD. The petition asserts that four prior‑art references render all asserted claims obvious under 35 U.S.C. §103. The case is currently pending before the PTAB.
Cellco Partnership d/b/a Verizon Wireless et al. v.Pegasus Wireless Innovation LLC
Cellco Partnership and other major carriers petition the PTAB to institute an IPR against Pegasus Wireless Innovation's ’931 patent covering MTC uplink control channel resource allocation, asserting obviousness over standard 3GPP references. The petition argues the Board should not deny institution under §325(d) or §314(a).
Precision Cancer Technologies Inc. v.Oncoustics Inc.
Precision Cancer Technologies Inc.'s IPR challenge against Oncoustics Inc. was denied by the PTAB, failing to meet the reasonable likelihood of prevailing standard. The Board found Petitioner failed to sufficiently demonstrate that prior art processed a 'single static set' of raw RF ultrasound data.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories challenged MIRACOR MEDICAL SA's heart assist pump patent (11754077) on grounds of obviousness over Wampler and Bourque. The PTAB instituted the IPR, affirming plain meanings for key terms like 'magneto coupling,' while finding Petitioner's rationale persuasive regarding combination art.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories successfully petitioned to institute IPR against MIRACOR MEDICAL SA's heart assist pump patent (US 11,572,879 B2). The Board adopted broader claim constructions for key terms like 'magneto coupling,' leading to institution on all 15 challenged claims.
M/S Shilpa Medicare Limited v.M/S. Salus Pharmaceuticals And Another
The defendants filed an application seeking rejection of the plaint on the grounds that the plaintiff had not demonstrated urgency and failed to comply with the mandatory requirement of pre-institution mediation under Section 12A of the Commercial Courts Act, 2015. The court found contradictions in the plaintiff's statements regarding when they became aware of the infringement and noted a significant delay between knowledge/patent grant and filing the suit.
United Spirits Limited & Anr. v.Globus Spirits Limited
In a recent order, the Delhi High Court addressed an application filed by Globus Spirits Limited seeking leave to cancel trademark registrations held by United Spirits Limited. The defendant argued that the plaintiffs' trademarks were not in use. The court accepted notice from the plaintiffs and directed them to file a reply within four weeks, followed by a rejoinder within two weeks, setting the next hearing for February 24, 2025.
Suinno Mobile & AI Technologies Licensing Oy v.Respondent
The applicant, Suinno Mobile & AI Technologies Licensing Oy, sought leave under Rule 263 of the Rules of Procedure to reduce the amount of damages sought in its infringement action against Microsoft Corporation concerning European patent EP 2 671 173 from the originally claimed sum to 2 million euros. Microsoft opposed the amendment, arguing it was a litigation tactic aimed at reducing the security for costs and did not fall within the scope of Rule 263. The Court held that the reduction of damages sought constitutes a limitation of the claim under Rule 263(3), and since it was filed with due explanation and unconditionally, leave to amend must be granted.
Myriad Service GmbH, Myriad Genetics, Inc., Myriad International GmbH, Myriad Genetics B.V., Eurobio Scientific, Myriad Genetics S.r.l., Myriad GmbH, Myriad Genetics S.A.S. v.Respondent
This procedural order from the Local Division Munich concerns a request by the defendants for the claimant to provide security for legal costs under Rule 158 RoP and Article 69(4) UPCA in a patent infringement action concerning European patent EP 3 346 403. The defendants argued that the claimant, a Korean IP monetization company incorporated in 2024 with limited assets and a low credit rating, posed a risk that any cost order would be unrecoverable. The claimant did not contest the request and agreed to provide security of EUR 112,000, and the court ordered the security to be provided by deposit or bank guarantee by 15 January 2025.
C-KORE SYSTEMS LIMITED v.Novawell
This procedural order was issued by the Paris Local Division following an interim conference held on 22 November 2024 in a patent infringement dispute concerning European Patent No. EP2265793 owned by C-Kore Systems Limited against French defendant Novawell. Novawell requested the rejection of exhibit 57 from C-Kore's unredacted statement, the hearing of the court's expert Mr. Sartorius and bailiff Me Labadie as witnesses, and simultaneous interpretation with French-language pleadings at the oral hearing, all of which C-Kore contested. The court addressed the scope of professional secrecy applicable to the affidavit submitted by Mr. Wlodarczyk, the representative present during the saisie (evidence preservation) operations, concluding that the information provided related to how the seizure measures were carried out and therefore fell outside the scope of professional secrecy under both UPC and French national rules.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Halozyme seeks Director Review to overturn the PTAB’s institution of a post‑grant review against its hyaluronidase patent, arguing filing‑date errors, improper claim construction, and Fintiv factors favoring denial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a petition to invalidate Halozyme’s ’298 patent covering modified PH20 polypeptides, arguing the claims lack written description and enablement. The reply attacks Halozyme’s reliance on functional language and disclaimed dependent claims.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s request for Director review after the PTAB instituted a post‑grant review of U.S. Patent 12,018,298 covering modified PH20 polypeptides. Merck argues the eligibility and claim‑construction issues are meritless and that the Fintiv factors favor institution.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories submits an authorized response urging the PTAB Director to deny Miracor Medical’s request for review of the institution decision, arguing the Board already resolved all substantive issues and that new Fintiv arguments are barred.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
The PTAB denied Director Review requests for three IPR institution decisions, including IPR2025-00115 concerning patent 11,674,517 owned by Miracor Medical and challenged by Abbott Laboratories. The institution decisions therefore remain in effect.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Miracor Medical seeks Director Review to deny Abbott’s institution of IPR 2025‑00115, arguing procedural deficiencies, lack of particularity, improper claim constructions, and word‑count violations. The Board had previously instituted the IPR on numerous cardiac‑pump claims.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s broad PH20 hyaluronidase patent, asserting lack of written description, enablement, and obviousness of the claimed protein variants.
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
Micron has petitioned the PTAB to invalidate 12 claims of Yangtze Memory’s 3D NAND ‘941 patent, asserting anticipation and obviousness over the Dong publication and combinations with Costa and Shirai. The petition seeks institution and argues no discretionary denial is warranted.
Tesla, Inc. v.Intellectual Ventures II
Tesla has filed an IPR petition seeking to invalidate Intellectual Ventures’ ’158 patent covering multi‑sensor digital cameras, arguing obviousness over Matsushima, Yu, and Miyazaki and opposing discretionary denial.
Tesla, Inc. v.Intellectual Ventures II
Tesla has filed an IPR petition seeking to invalidate 12 claims of Intellectual Ventures’ U.S. Patent 10,952,153 covering uplink power‑control techniques, arguing the claims are obvious over multiple prior‑art references and that discretionary denial is unwarranted.
Tesla, Inc. v.Intellectual Ventures II
Tesla seeks IPR institution to invalidate claims 11‑22 of Intellectual Ventures’ ’500 patent, arguing they are obvious over multiple prior‑art references covering uplink power control. The petition also argues that discretionary denial is inappropriate.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of Miracor’s LVAD patent (U.S. 11,376,415). The petition argues that the claims are obvious in view of four prior‑art references covering magnetically driven rotary pumps.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s 11,674,517 LVAD patent, asserting that all 19 challenged claims are obvious over four prior‑art references. The petition argues that the prior art discloses every claim limitation and that discretionary denial is unwarranted.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of Miracor Medical’s 357 Patent covering a magnetically levitated LVAD. The petition relies on four prior‑art references to argue that all challenged claims are obvious under 35 U.S.C. §103.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.